CRISPR Therapeutics AG
News
1 Biotech Stock Down 62% to Buy and Hold
Fool.com Headlines In the past three years, CRISPR Therapeutics (NASDAQ: CRSP) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in...\n more…
Private Advisor Group LLC Increases Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Ticker Report Private Advisor Group LLC lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 472.9% during the second quarter, according to the company in its most recent filing with the...\n more…
Commonwealth Equity Services LLC Purchases 7,560 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Ticker Report Commonwealth Equity Services LLC raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 14.0% in the 2nd quarter, according to its most recent Form 13F filing with the...\n more…
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
Zacks Investment Research CRISPR Therapeutics AG (CRSP) closed the latest trading day at $45.51, indicating a +1.42% change from the previous session's end. The stock outpaced the S&P 500's daily gain of 0.45%. Elsewhere, the...\n more…
Larson Financial Group LLC Acquires 276 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Zolmax Larson Financial Group LLC raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 95.5% during the 2nd quarter, according to its most recent filing with the Securities...\n more…